Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment.

@article{Nesher1997ValvularDI,
  title={Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment.},
  author={Gideon Nesher and Jacob Ilany and David Rosenmann and Abraham S. Abraham},
  journal={Seminars in arthritis and rheumatism},
  year={1997},
  volume={27 1},
  pages={27-35}
}
Valvular abnormalities develop in 36% and 35% of patients with primary antiphospholipid syndrome (PAPS) and with systemic lupus erythematosus (SLE) respectively, and in 48% of patients with SLE and antiphospholipid antibodies (aPL). Valvulopathy includes leaflet thickening, vegetations, regurgitation, and stenosis. A literature survey shows that significant morbidity from valvular dysfunction, mostly mitral regurgitation leading to congestive heart failure, occurs in 4% and 6% of SLE and PAPS… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…